Markets

CLINUVEL (NASDAQ:CLVLY) announced advancements in novel sustained-release liquid drug formulations after 10 years of research. The company is proceeding to preclinical evaluation of drug release profiles, aiming to extend peptide drug release, especially melanocortins, using biocompatible systems for flexible dosing. This technology may benefit diverse patient groups. The preclinical program’s completion is expected in H2 2026. The new depot formulations would serve as a platform for the delivery of various peptides, with an initial focus on melanocortins.

Tommy Fleetwood received the Nicklaus-Jacklin Award after the 2025 Ryder Cup, recognizing his embodiment of the event’s spirit through integrity and sound decision-making. Fleetwood’s impressive 4-1-0 record contributed significantly to Team Europe’s victory. Beyond his performance, his composure and sportsmanship, echoing the 1969 Nicklaus-Jacklin moment, earned him the honor. Aon, the award presenter, highlighted Fleetwood’s leadership and ability to make better decisions under pressure, mirroring Aon’s values. Team Europe secured a 15-13 victory overall, winning on US soil.

Barton Gold has commenced a Definitive Feasibility Study for Stage 1 production at its Challenger Gold Project in South Australia. The project leverages the fully permitted Central Gawler Mill and boasts a JORC Mineral Resource Estimate of 313koz Au, including 194koz Au of high-grade fresh ore. The company plans a two-phase approach involving tailings reprocessing followed by high-grade ore introduction. DFS completion and commissioning are targeted by March and the end of 2026, respectively. However, production isn’t expected until late 2026 and financing is still under discussion.

Larimar Therapeutics (LRMR) will host a conference call and webcast on September 29, 2025, at 8:00 am EDT to provide updates on its nomlabofusp clinical development program. The presentation will feature data from the ongoing long-term open-label study evaluating nomlabofusp for the treatment of Friedreich’s ataxia (FA). The company aims to demonstrate the drug’s long-term efficacy and safety in FA patients, addressing a significant unmet medical need. A webcast replay will be available on Larimar’s website.

Coherent Corp. will unveil optical communication advancements at ECOC 2025 in Copenhagen, showcasing solutions for AI/ML data centers and next-generation networking. Key highlights include a 2D VCSEL Array, a 100G ZR dual-laser QSFP28 DCO module, and a 400mW CW Laser for co-packaged optics. Coherent will also demonstrate quantum-safe networking and high-speed transceivers. Executives will participate in discussions on transceiver evolution and manufacturing co-packaged optics.

MoonLake Immunotherapeutics announced Phase 3 VELA program results for sonelokimab in moderate to severe hidradenitis suppurativa (HS). The combined trials showed statistically significant improvements in primary and key secondary endpoints. VELA-1 achieved statistical significance, while VELA-2 missed its primary endpoint due to a higher placebo response. Both trials showed noteworthy HiSCR75 results using a pre-specified treatment policy strategy. Sonelokimab exhibited a favorable safety profile. MoonLake plans regulatory discussions and continues clinical studies in multiple indications.

BridgeBio Pharma’s acoramidis (Attruby®/BEYONTTRA®) shows rapid efficacy in treating transthyretin amyloid cardiomyopathy (ATTR-CM). The ATTRibute-CM study revealed a 49% reduction in cardiovascular mortality or recurrent hospitalizations by Month 30. Extended follow-up showed a 45% reduction in cardiovascular mortality at Month 42 compared to placebo switch. Acoramidis, an oral TTR stabilizer, is approved in the US, Europe, Japan, and the UK, demonstrating near-complete TTR stabilization. It also mitigates rises in NT-proBNP levels.

Ensurge Micropower ASA (ENMPY) granted 10,390,000 incentive subscription rights to key employees under its 2025 plan. Primary insiders, including CFO Lars Eikeland (2,000,000 SRs) and EVP Arvind Kamath (2,100,000 SRs), received significant allocations. The company develops ultrathin, flexible solid-state lithium microbatteries, focusing on prototyping and small-scale manufacturing while planning to outsource large-scale production. Their technology development is based in Silicon Valley.

MetLife Foundation has committed $9 million to the FIFA Global Citizen Education Fund as part of a three-year partnership with Global Citizen to eradicate extreme poverty. MetLife’s involvement includes employee volunteer programs and leveraging its global network to promote education and economic empowerment. The MetLife Foundation’s donation is a founding investment toward the fund’s $100 million goal to promote global access to education and sports. MetLife will also support Global Citizen events. This partnership highlights the growing trend of corporations integrating ESG principles.

HII announced the successful completion of builder’s sea trials for the *Ted Stevens* (DDG 128), a Flight III Arleigh Burke-class destroyer. These trials validated the vessel’s systems, including the advanced AN/SPY-6(V)1 radar. HII has delivered 35 Arleigh Burke-class destroyers and currently has five Flight III destroyers under construction. To meet demand, HII is partnering with other shipyards to expand production capacity. The Flight III destroyers feature the Aegis Baseline 10 combat system.